Výsledky vyhledávání - "Martha, Mayo"

Akademický článek

Optimized Culture Conditions for Improved Growth and Functional Differentiation of Mouse and Human Colon Organoids

Autor: Sarah S. Wilson, Martha Mayo, Terry Melim, Heather Knight, Lori Patnaude, Xiaoming Wu, Lucy Phillips, Susan Westmoreland, Robert Dunstan, Edda Fiebiger, Sonia Terrillon

Publikováno v: Frontiers in Immunology, Vol 11 (2021)

Background & AimsDiligent side-by-side comparisons of how different methodologies affect growth efficiency and quality of intestinal colonoids have not been performed leaving a gap in our current knowledge. Here, we summarize our efforts to optimize

Externí odkaz: https://doaj.org/article/c5eb0eb4a5604398a00805aba1307b2b

Zobrazit plný text záznamu

Akademický článek

NRF2 activator A-1396076 ameliorates inflammation in autoimmune disease models by inhibiting antigen dependent T cell activation

Autor: Christian Goess, Sonia Terrillon, Martha Mayo, Peter Bousquet, Craig Wallace, Michelle Hart, Suzanne Mathieu, Rachel Twomey, Diana Donnelly-Roberts, Marian Namovic, Paul Jung, Min Hu, Paul Richardson, Tim Esbenshade, Carolyn A. Cuff

Publikováno v: Journal of Translational Autoimmunity, Vol 4, Iss , Pp 100079- (2021)

Nuclear factor (erythroid-derived 2) like 2 (NRF2) is a nuclear transcription factor activated in response to oxidative stress that induces a gene program that dampens inflammation and can limit cell damage that perpetuates the inflammatory response.

Externí odkaz: https://doaj.org/article/36bd7d69d8334e0fbee64f2bdb063450

Zobrazit plný text záznamu

Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial

Autor: Patrick Rossignol, Jeffrey Budden, Martha Mayo, Rajiv Agarwal, William B. White, Bryan Williams, Susan Arthur

Publikováno v: Kidney360

BACKGROUND: Mineralocorticoid receptor antagonists reduce mortality in patients with heart failure with reduced ejection fraction and have become a standard of care in those with resistant hypertension (rHTN). Yet, their use is limited among patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486d15df4401425e760b73f3f8b8b9ed
https://doi.org/10.34067/kid.0006782020

Zobrazit plný text záznamu

Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes

Autor: Bryan Williams, Ansgar Conrad, Patrick Rossignol, Martha Mayo, Rajiv Agarwal, William B. White, Susan Arthur

Publikováno v: Clin J Am Soc Nephrol

Spironolactone is recommended in patients with resistant hypertension, including those with diabetes ([1][1]). However, spironolactone increases hyperkalemia risk, which can limit use in patients with diabetes ([2][2]). AMBER (ClinicalTrials.gov [NCT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e3d862ffcaeabdf9bd92c8bb0c456a
https://europepmc.org/articles/PMC8729584/

Zobrazit plný text záznamu

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

Autor: Rajiv Agarwal, Patrick Rossignol, Bryan Williams, Alain Romero, Martha Mayo, William B. White, Jia Ma, Suzette Warren, Dahlia Garza

Publikováno v: The Lancet. 394:1540-1550

Summary Background Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::209a6a5c2084f25349d54060ab1dfb19
https://doi.org/10.1016/s0140-6736(19)32135-x

Zobrazit plný text záznamu

NRF2 activator A-1396076 ameliorates inflammation in autoimmune disease models by inhibiting antigen dependent T cell activation

Autor: Paul M. Jung, Craig Wallace, Sonia Terrillon, Rachel Twomey, Paul L. Richardson, Peter Bousquet, Min Hu, Michelle Hart, Carolyn A. Cuff, Christian Goess, Tim Esbenshade, Martha Mayo, Marian Namovic, Diana Donnelly-Roberts, Suzanne Mathieu

Publikováno v: Journal of Translational Autoimmunity, Vol 4, Iss, Pp 100079-(2021)
Journal of Translational Autoimmunity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc9cdbaab56bee492ed2de9ce8cca61c
http://www.sciencedirect.com/science/article/pii/S2589909020300460

Zobrazit plný text záznamu

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure

Autor: Patrick Rossignol, Rajiv Agarwal, Gail Ackourey, William B. White, Susan Arthur, Bryan Williams, Martha Mayo, Suzette Warren

Publikováno v: European Journal of Heart Failure
European Journal of Heart Failure, 2020, 22 (8), pp.1462-1471. ⟨10.1002/ejhf.1860⟩
European Journal of Heart Failure, Oxford University Press (OUP), 2020, 22 (8), pp.1462-1471. ⟨10.1002/ejhf.1860⟩

International audience; Aims: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::118c043ac093b6ae18c0caf7b27618d5
https://hal.univ-lorraine.fr/hal-03020061/document

Zobrazit plný text záznamu

Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN

Autor: Lance Berman, Martha Mayo, Bertram Pitt, Mitja Lainscak, George L. Bakris, Matthew R. Weir, Rezi Zawadzki, Mason W. Freeman, David A. Bushinsky, Dahlia Garza

Publikováno v: ESC Heart Failure. 5:592-602

Aims Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free, non-absorbed potassium b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b692f84eb2d7e0172ab604a7585d902f
https://doi.org/10.1002/ehf2.12292

Zobrazit plný text záznamu

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

Autor: Bryan Williams, Rajiv Agarwal, Alain Romero, Martha Mayo, Dahlia Garza, Suzette Warren, Susan Arthur, Patrick Rossignol, William B. White

Publikováno v: American Journal of Nephrology. 48:172-180

Background: While chronic kidney disease (CKD) is common in resistant hypertension (RHTN), prior studies evaluating mineralocorticoid receptor antagonists excluded patients with reduced kidney function due to risk of hyperkalemia. AMBER (ClinicalTr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e958dfd401f6c3b46a75ca67c5e4c94
https://doi.org/10.1159/000492622

Zobrazit plný text záznamu

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

Autor: Martha Mayo, Susan Arthur, Murray Epstein, Matthew R. Weir, Lance Berman, Dahlia Garza, David A. Bushinsky, Daniel J. Wilson

Publikováno v: Journal of Hypertension

Objective: Recurrent hyperkalemia frequently limits use of renin–angiotensin–aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD) patients with hypertension, diabetes, and/or heart failure. Patiromer is a sodium-free, nonabsorbed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987b2f62e73da50d70878a48d9820a14
https://doi.org/10.1097/hjh.0000000000001278

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání